Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBuckley, Rachel F-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorEllis, Kathryn A-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorJohnson, Keith-
dc.contributor.authorSperling, Reisa-
dc.contributor.authorAmariglio, Rebecca-
dc.identifier.citationJournal of Molecular Neuroscience 2016; online first: 11 Augusten
dc.description.abstractThis commentary outlines a conceptual model for subjective cognitive decline (SCD) in relation to Alzheimer's disease (AD) biomarkers in the preclinical stages of disease and a framework for effectively utilizing SCD in secondary prevention clinical trials. Mounting evidence supports the notion that SCD is sensitive to encroaching Aβ-amyloid and neurodegeneration. SCD has also been shown to provide additive information of AD-dementia risk beyond what is known about the biomarker status of the individual. Thus, we provide recommendations for the implementing SCD measurement in clinical trials. We argue that SCD can be measured at three catch points within the course of the clinical trial: firstly, at the initial recruitment and screening phase; secondly, to create more robust estimates of rates of AD-dementia progression; and finally, to measure subjective experiences of cognitive change and quality of life over the course of the trial as a proxy of clinically meaningful functional improvement. We provide recommendations of how SCD can be approached at each of these points. SCD is an important component of the preclinical AD-dementia trajectory. Future studies need to elucidate the interactive influence of Aβ-amyloid and tau on SCD from a spatiotemporal perspective. Even as this evidence accrues, it is clear that SCD can provide unique and additive information about rates of progression and subjectively experienced cognitive change within clinical trials.en
dc.subjectAlzheimer’s diseaseen
dc.subjectSubjective cognitive declineen
dc.titleA conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer's diseaseen
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Molecular Neuroscienceen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationMelbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationCentre for Alzheimer Research and Treatment, Department of Neurology, Brigham Women's Hospital/Harvard Medical School, Boston, MA, USAen
dc.identifier.affiliationAthinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Boston, MA, USAen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationThe Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USAen
dc.identifier.affiliationDepartment of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USAen
dc.type.austinJournal Articleen_US, Colin L
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.grantfulltextnone- Imaging and Therapy- Florey Institute of Neuroscience and Mental Health- Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jul 25, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.